4 research outputs found

    Arthrodarin – a new drug for osteoarthritis pathogenetic therapy

    No full text
    Остеоартроз (ОА) является одним из наиболее распространенных заболеваний опорно-двигательного аппарата, особенно у лиц старшей возрастной группы.С современных позиций ОА рассматривается как гетерогенная группа заболеваний, имеющих различную этиологию, но сходные биологические, морфологические и клинические черты.Патологический процесс при ОА затрагивает не только хрящ, но и субхондральную кость, связки, капсулу сустава, а также периартикулярные мышцы, синовиальную оболочку, в которой развивается основной воспалительный процесс, приводящий к нарушению структуры хряща, образованию вначале поверхностных его повреждений, а затем глубоких трещин, формированию остеофитов, нарушению конгруэнтности суставных поверхностей. Следствием этих процессов является боль, нарушение функции сустава, ухудшение качества жизни пациентов вплоть до потери трудоспособности и инвалидизации [1, 2]. Диагноз ОА, несмотря на технический прогресс и внедрение в медицинскую практику сонографии суставов, компьютерной томографии, магнитно-резонансной техники, часто ставится на поздних сроках болезни из-за отсутствия болевого синдрома, который является основной причиной обращаемости больного к врачу

    INFECTION ASSOCIATED WITH THE IMPLANTATION OF CARDIOVASCULAR IMPLANTABLE ELECTRONIC DEVICES

    No full text
    Data on the frequency, nature, risk factors and diagnosis of infectious complications (IC) in patients with cardioimplanted electronic devices (CED) — artificial rhythm drivers, cardiodefibrillators, devices for cardiosynchronizing therapy — often prognostically unfavorable, accompanied by high mortality, are given in the article. The data of a large-scale retrospective analysis of 200 219 patients with CED are given during the 3-year period after implantation. It was noted that among persons with IC there was a higher mortality rate compared to patients without signs of infection. In the analysis of cases of IC, the main risk factors for their development are identified, including. Presence of concomitant pathology. This article discusses the basic types of microorganisms were isolated from patients with the presence of IC, IC clinical symptoms, provides a diagnostic algorithm for suspected IC. A feature of the clinical case presented in the article is a relatively early development of IC with damage to the valve structures (tricuspid valve) — the first symptoms of bacterial damage appeared 6 months after the operation. Usually infectious endocarditis in patients with CED was verified at various times after implantation — from 1 to 72 months, and in most cases not earlier than 3 months later. The main clinical manifestations of the disease were recurrent fever, which is why the patient was repeatedly hospitalized for several months in various medical institutions. In each hospital, the patient management tactics were different and did not meet the accepted standards of diagnostic search in a febrile patient with CED. Only with the third hospitalization of the patient (November 2015) during the transthoracic echocardiography were revealed vegetations on the valves of the tricuspid valve. The given clinical observation testifies not only to the difficulties of diagnosing IE in patients with the presence of CED, but also about the inevitable mistakes in maintaining this category of patients when the standards for diagnosis and treatment of IE are not complied with. The authors emphasize that in the course of diagnostic search, and later in the development of treatment tactics, it is necessary to follow the ESC Guidelines for the management of infective endocarditis in 2015

    Clinical efficacy of native drug Adgelon in knee osteoarthritis

    No full text
    Results of treatment of 76 pts with knee osteoarthritis with native drug Adgelon (glycoprotein possessing biological activity at super low doses) are presented. WOMAC index, Lequesne functional index and SF-36 questionnaire show analgesic effect and quality of life improvement after 6 intra-articular adgelon injections during 3 weeks. Subsequent follow up for 2 months revealed aftereffect of the drug
    corecore